Previous Experience

I have held a succession of senior executive positions in biotechnology, pharmaceutical, medical device companies, and diagnostic companies in the USA, Europe and Asia.

Current Positions:

  • President, Owner and Founder of Mark Philip Consulting LLC.
    • Providing consulting service in the areas of strategy development, product development, business development, fund raising, commercial planning to a range of small and large pharmaceutical, biotechnology, medical device and diagnostic companies
  • Lecturer, Boston University School of Management, Health Management MBA Program, Operations and Technology Department.

Past Positions:

  • Chief Operating Officer, Portal Instruments Inc., a medical device company that has solved the drug administration of monoclonal antibodies for pharmaceutical companies.
  • Non-Executive Chairman, President and Board Member of Biousian Bioscience Inc., a biotechnology company based in Boston, MA, focused on GPCR agonist development, with a lead drug targeting neuropathic and inflammatory pain.
  • Acting Chief Operating Officer forĀ SynapDx, Inc., and diagnostic company focused on Autism Spectrum Disorders and other Development Disorders with a unique platform technology capable of discerning genomic differences between closely associated diseases
  • President, CEO and Board Member of Znomics, Inc., (OTCBB: ZNOM), a biotech company discovering novel small molecules: sold to Cherry Tree.
  • President of Stryker Biotech: reinvigorated the strategy, turned around manufacturing, created an R&D plan, hired a top rate team, and grew sales 500%.
  • President, CEO and Board Member of Zycos, Inc., a biotechnology: raised over $55 million in venture finance, successfully negotiated multi-million dollar partnership deals, developed a panel of drugs from inception to phase 2 clinical data culminating in a sale of the company to MGI Pharma.
  • Board Member of Cohesion Technologies Inc (NASDAQ: CSON), a mid-size medical device company: launched two new products; sold to Angiotech.
  • President and CEO of Immuno-U.S., a mid-size pharma company listed on the Swiss Stock Exchange. Grew sales growth of 100%, turned around operations, grew profits 11 fold, sold to Baxter International.
  • Senior management positions at Baxter International in Europe, USA and Japan focused on the development and commercialization of a wide range of drugs, devices and services in renal medicine.
  • Management positions in Schering Plough (Kirby Warrick Pharmaceuticals) and Boots Pharmaceuticals in the UK.

Mark Philip Qualifications

Industry Experience